<code id='0E69DA0B63'></code><style id='0E69DA0B63'></style>
    • <acronym id='0E69DA0B63'></acronym>
      <center id='0E69DA0B63'><center id='0E69DA0B63'><tfoot id='0E69DA0B63'></tfoot></center><abbr id='0E69DA0B63'><dir id='0E69DA0B63'><tfoot id='0E69DA0B63'></tfoot><noframes id='0E69DA0B63'>

    • <optgroup id='0E69DA0B63'><strike id='0E69DA0B63'><sup id='0E69DA0B63'></sup></strike><code id='0E69DA0B63'></code></optgroup>
        1. <b id='0E69DA0B63'><label id='0E69DA0B63'><select id='0E69DA0B63'><dt id='0E69DA0B63'><span id='0E69DA0B63'></span></dt></select></label></b><u id='0E69DA0B63'></u>
          <i id='0E69DA0B63'><strike id='0E69DA0B63'><tt id='0E69DA0B63'><pre id='0E69DA0B63'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot